SLEEP 2023, the 37th annual meeting of the Associated Professional Sleep Societies LLC (APSS), was held on June 3-7, 2023 in Indianapolis, Indiana. Since its inception in 1986, SLEEP has become the premier forum on sleep medicine. Each year, the APSS is proud to bring together a diverse and dedicated group of attendees, speakers, and exhibitors to contribute to the advancement of sleep medicine. Below are some of the research findings and product announcements from this year’s exhibitors.
Avadel Pharmaceuticals announced new data supporting the clinical profile for LUMRYZ™ (sodium oxybate) for extended-release oral suspension (CIII) and patient preference for a once-nightly oxybate in 12 abstracts, including six oral presentations, at SLEEP 2023.
Axsome Therapeutics, Inc. held several presentations on Sunosi® (solriamfetol) at SLEEP 2023.
Eisai Co., Ltd. presented a total of eight poster presentations, including the latest data on its in-house discovered orexin receptor antagonist lemborexant (product name: DAYVIGO®), at SLEEP 2023.
Harmony Biosciences presented new safety and efficacy data from a phase 2 proof-of-concept study evaluating pitolisant for the treatment of excessive daytime sleepiness in patients with Prader-Willi syndrome (PWS) at SLEEP 2023.
Inspire Medical Systems presented multiple sessions and held several poster presentations at SLEEP 2023 that included sharing the outcomes of Inspire therapy and real-world evaluation of system quality using post-market surveillance data.
Jazz Pharmaceuticals presented seven abstracts featuring new data from across its sleep medicine portfolio at SLEEP 2023.
LifeQ unveiled a new sleep solution for clinicians and patients that aims to uncover sleep disorders, achieve greater sleep quality, and improve health and wellness at SLEEP 2023.
NLS Pharmaceutics presented clinical data for the lead compound, Mazindol ER, as well as preclinical data on its pipeline compound, NLS-4, at SLEEP 2023.
Onera Health announced the formation of a Medical Advisory Board ahead of SLEEP 2023, where the company exhibited and presented two poster abstracts.
ResMed presented on the global prevalence of mild obstructive sleep apnea among women and PAP’s cost-saving abilities at SLEEP 2023.
Sunrise presented two new studies involving mandibular jaw movements at SLEEP 2023.